journal article·2017-07-05

Enhanced Immune Adjuvant Activity of Aluminum Oxyhydroxide Nanorods through Cationic Surface Functionalization

Bingbing Sun, Zhaoxia Ji, Yu-Pei Liao, Chong Hyun Chang, Xiang Wang, Justine Ku, Changying Xue, Vahid Mirshafiee, Tian Xia

Publisher page

Abstract

Aluminum-salt-based vaccine adjuvants are prevailingly used in FDA-approved vaccines for the prevention of infectious diseases for over eighty years. Despite their safe applications, the mechanisms regarding how the material characteristics affect the interactions at nano–bio interface and immunogenicity remain unclear. Recently, studies have indicated that the activation of NLRP3 inflammasome plays a critical role in inducing adjuvant effects that are controlled by the inherent shape and hydroxyl contents of aluminum oxyhydroxide (AlOOH) nanoparticles; however, the detailed relationship between surface properties and adjuvant effects for these materials remains unknown. Thus, we engineered AlOOH nanorods (ALNRs) with controlled surface functionalization and charge to assess their effects on the activation of NLRP3 inflammasome in vitro and the potentiation of immunogenicity in vivo. It is demonstrated that NH 2 -functionalized ALNRs exhibited higher levels of cellular uptake, lysosomal damage, oxidative stress, and NLRP3 inflammasome activation than pristine and SO 3 H-functionalized ALNRs in cells. This structure–activity relationship also correlates with the adjuvant activity of the material using ovalbumin (OVA) in a mouse vaccination model. This study demonstrates that surface functionalization of ALNRs is critical for rational design of aluminum-based adjuvants to boost antigen-specific immune responses for more effective and long-lasting vaccination.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticles: synthesis and applications · Curcumin's Biomedical Applications · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Fine Chemicals, School of Chemical Engineering, and ⊥School of Life Science and Biotechnology, Dalian University of Technology, 2 Linggong Road, 116024 Dalian, China

Division of NanoMedicine, Department of Medicine, §California NanoSystems Institute, and ∥Department of Ecology and Evolutionary Biology, University of California, Los Angeles, California 90095, United States

Funding

National Institute of Environmental Health Sciences · Division of Biological Infrastructure · National Natural Science Foundation of China · Central Committee of the Communist Party of China

References (58)

Show source-provided references
1. 10.1038/nm120910.1038/nm1209 ↗
2. 10.1586/14760584.6.5.68510.1586/14760584.6.5.685 ↗
3. 10.1038/nri308510.1038/nri3085 ↗
4. 10.1016/j.addr.2007.05.01710.1016/j.addr.2007.05.017 ↗
5. 10.1016/j.vaccine.2017.01.05410.1016/j.vaccine.2017.01.054 ↗
6. 10.1016/j.vaccine.2016.03.03710.1016/j.vaccine.2016.03.037 ↗
7. 10.1016/s0264-410x(02)00166-410.1016/s0264-410x(02)00166-4 ↗
8. 10.1039/c6tb01131d10.1039/c6tb01131d ↗
9. 10.1016/j.jconrel.2010.03.02710.1016/j.jconrel.2010.03.027 ↗
10. 10.1002/path.170034021410.1002/path.1700340214 ↗
11. 10.1016/j.vaccine.2012.11.04410.1016/j.vaccine.2012.11.044 ↗
12. 10.1038/nature0693910.1038/nature06939 ↗
13. 10.1002/smll.20120196210.1002/smll.201201962 ↗
14. 10.1021/nn404211j10.1021/nn404211j ↗
15. 10.1016/j.vaccine.2004.07.05010.1016/j.vaccine.2004.07.050 ↗
16. 10.1038/nm.230610.1038/nm.2306 ↗
17. 10.1038/nmat244210.1038/nmat2442 ↗
18. 10.1016/j.ymthe.2017.03.01110.1016/j.ymthe.2017.03.011 ↗
19. 10.1039/c1nr10166h10.1039/c1nr10166h ↗
20. 10.1016/j.biomaterials.2015.03.01310.1016/j.biomaterials.2015.03.013 ↗
21. 10.1016/j.jconrel.2013.10.03210.1016/j.jconrel.2013.10.032 ↗
22. 10.1021/acsami.5b0034810.1021/acsami.5b00348 ↗
23. 10.1073/pnas.142292311210.1073/pnas.1422923112 ↗
24. 10.1016/j.ijpharm.2008.06.02910.1016/j.ijpharm.2008.06.029 ↗
25. 10.1111/j.1365-2567.2007.02560.x10.1111/j.1365-2567.2007.02560.x ↗
26. 10.1016/j.actbio.2011.09.01410.1016/j.actbio.2011.09.014 ↗
27. 10.1021/nl300895y10.1021/nl300895y ↗
28. 10.4049/jimmunol.168.5.256010.4049/jimmunol.168.5.2560 ↗
29. 10.1088/0957-4484/20/21/21560410.1088/0957-4484/20/21/215604 ↗
30. 10.1021/ja304907c10.1021/ja304907c ↗
31. 10.1021/acsnano.5b0344310.1021/acsnano.5b03443 ↗
32. 10.1021/nn700256c10.1021/nn700256c ↗
33. 10.1016/j.biomaterials.2010.05.03610.1016/j.biomaterials.2010.05.036 ↗
34. 10.1021/nn301211410.1021/nn3012114 ↗
35. 10.1038/ni.163110.1038/ni.1631 ↗
36. 10.4049/jimmunol.080269610.4049/jimmunol.0802696 ↗
37. 10.1002/smll.20140285910.1002/smll.201402859 ↗
38. 10.1016/s0165-2478(00)00188-710.1016/s0165-2478(00)00188-7 ↗
39. 10.1016/j.vaccine.2006.09.03910.1016/j.vaccine.2006.09.039 ↗
40. 10.1038/nm.240310.1038/nm.2403 ↗
41. 10.1016/j.jconrel.2008.05.00510.1016/j.jconrel.2008.05.005 ↗
42. 10.1038/ni.183110.1038/ni.1831 ↗
43. Warren J. S. · 1988 · 29910.1007/978-1-4684-5496-3_14 ↗
44. 10.1007/bf0092607210.1007/bf00926072 ↗
45. 10.1074/jbc.m00894420010.1074/jbc.m008944200 ↗
46. 10.1074/jbc.m30191120010.1074/jbc.m301911200 ↗
47. 10.1074/jbc.c40037420010.1074/jbc.c400374200 ↗
48. 10.1042/bj2002112110.1042/bj20021121 ↗
49. 10.1074/jbc.273.19.1140110.1074/jbc.273.19.11401 ↗
50. 10.1126/science.111439710.1126/science.1114397 ↗
51. 10.1016/s0952-7915(97)80153-710.1016/s0952-7915(97)80153-7 ↗
52. 10.1146/annurev.immunol.20.100301.06482810.1146/annurev.immunol.20.100301.064828 ↗
53. 10.1080/0968786060079053710.1080/09687860600790537 ↗
54. 10.1016/j.ijpharm.2003.10.03810.1016/j.ijpharm.2003.10.038 ↗
55. 10.4161/hv.4.1.488610.4161/hv.4.1.4886 ↗
56. 10.1016/j.exppara.2008.12.01510.1016/j.exppara.2008.12.015 ↗
57. 10.1016/0923-2494(92)80060-x10.1016/0923-2494(92)80060-x ↗
58. 10.1016/j.vaccine.2010.08.00210.1016/j.vaccine.2010.08.002 ↗